Back to Report Store Home

Global Dermatology Drugs Market to 2024 – IL Signaling Inhibitors to Overtake TNF-a Inhibitors as Leading Commercial Drug Class with Dupixent and Cosentyx among Key Performers

  • Published: Dec-2018
  • Report Code: GBIHC486MR
  • Report Format: pdf

Description

List of Tables

Table 1: Dermatology Drugs Market , Global, Classification of Atopic Dermatitis Severity and Impact on Quality of Life, 2018 14

Table 2: Dermatology Drugs Market , Global, Comparison of Acne Grading Scales Used in Europe and the US, 2018 15

Table 3: Dermatology Drugs Market, Global, Classification of Psoriasis Severity, 2018 16

Table 4: Dermatology Drugs Market, 7MM, Epidemiology of Dermatological Disorders, 2018 21

Table 5: Dermatology Drugs Market, Global, Approved Dermatology Indications for Humira, 2018 31

Table 6: Dermatology Drugs Market, Global, Approved Dermatology Indications for Enbrel, 2018 33

Table 7: Dermatology Drugs Market, Global, Approved Dermatology Indications for Remicade, 2018 35

Table 8: Dermatology Drugs Market, Global, Approved Dermatology Indications for Stelara, 2018 37

Table 9: Dermatology Drugs Market, Global, Approved Dermatology Indications for Cosentyx, 2018 38

Table 10: Dermatology Drugs Market, Global, Approved Dermatology Indications for Taltz, 2018 40

Table 11: Dermatology Drugs Market, Global, Approved Dermatology Indications for Dupixent, 2018 42

Table 12: Dermatology Drugs Market, Global, Approved Dermatology Indications for Eucrisa, 2018 43

Table 13: Dermatology Drugs Market, Global, Approved Dermatology Indications for Neoral, 2018 44

Table 14: Dermatology Drugs Market, Global, Approved Dermatology Indications for Protopic, 2018 46

Table 15: Dermatology Drugs Market, Global, Approved Dermatology Indications for Elidel, 2018 47

Table 16: Dermatology Drugs Market, Global, Approved Dermatology Indications for Differin, 2018 49

Table 17: Dermatology Drugs Market, Global, Approved Dermatology Indications for Elocon, 2018 50

Table 18: Dermatology Drugs Market, Global, Approved Dermatology Indications for Clobex, 2018 52

Table 19: Dermatology Drugs Market, Global, Approved Dermatology Indications for Aczone, 2018 53

Table 20: Dermatology Drugs Market, Global, Approved Dermatology Indications for Retin-A, 2018 55

Table 21: Dermatology Drugs Market, Global, Approved Dermatology Indications for Episalvan, 2018 56

Table 22: Dermatology Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2017–2024 87

Table 23: Dermatology Drugs Market, Global, Usage of Generics Across Key Indications, 2018 89

Table 24: Dermatology Drugs Market, Global, Forecast Revenue by Company, 2017–2024 101

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards